{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:56:01Z","timestamp":1783436161455,"version":"3.54.6"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The efficacy and safety of an abbreviated duration of dual antiplatelet therapy (DAPT) in patients with high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) (PCI-HBR patients) remain controversial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The Cochrane Library, PubMed, EMBASE, and Ovid MEDLINE databases were searched. Studies that enrolled PCI-HBR patients as research subjects, compared different DAPT durations, and reported incidences of major adverse cardiac events (MACE) and net adverse clinical events (NACE) in PCI-HBR patients were obtained. The studies were stratified according to the DAPT duration (1, 3, and 6 months), and meta-analysis was subsequently performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Nine studies (10 cohorts) were included in the meta-analysis. Compared with those who received DAPT for &gt;1 month, PCI-HBR patients who received the 1-month DAPT regimen had comparable risks of NACE and MACE. Compared to those who received DAPT for &gt;3 months, the risk of developing MACE in PCI-HBR patients who received the 3-month DAPT was not increased; however, the risk of ischemic stroke and stent thrombosis increased. Compared to those who received DAPT for &gt;6 months, patients who received the 6-month DAPT had a reduction in the risk of major bleeding without an increase in NACE and MACE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Shortening the DAPT regimen to 1 or 6 months did not increase the risk of MACE, and the 6-month DAPT regimen reduced the risk of major bleeding. However, the 3-month DAPT regimen increased the risk of ischemic stroke. Thus, shortened DAPT reduced the risk of MACE and bleeding, with a small absolute increase in ischemic strokes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001180","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T14:04:09Z","timestamp":1664546649000},"page":"580-589","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Short dual antiplatelet therapy in patients with high bleeding risk undergoing percutaneous coronary intervention: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"33","author":[{"given":"Junyan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxiu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duolao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"He","sequence":"additional","affiliation":[{"name":"West China Hospital, West China School of Medicine, Sichuan University, Chengdu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Community Health Center of XinBei Hi-Tech Zone"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangbo","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Community Health Center of Huaxing Wuhou District, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","article-title":"Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.","volume":"4","author":"Mehran","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"R2-20250729","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.","volume":"38","author":"Valgimigli","year":"2016","journal-title":"Eur Heart J"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk.","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/MCA.0000000000000885","article-title":"Association between mean platelet volume and major adverse cardiac events in percutaneous coronary interventions: A systematic review and meta-analysis.","volume":"31","author":"Chen","year":"2020","journal-title":"Coron Artery Dis"},{"key":"R7-20250729","first-page":"e010144","article-title":"Primary Results of the EVOLVE Short DAPT Study.","volume":"14","author":"Kirtane","year":"2021","journal-title":"Circulation: Cardiovascular Interventions"},{"issue":"Suppl 2","key":"R8-20250729","first-page":"1025","article-title":"Impact of 6- versus 12-month dual antiplatelet therapy on clinical prognosis in patients with high bleeding risk: Insights from the 4-year results of the I LOVE IT 2 study.","volume":"97","author":"Zhang","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting.","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"e002524","DOI":"10.1161\/JAHA.115.002524","article-title":"Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy.","volume":"4","author":"Costa","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"R11-20250729","first-page":"e008530","article-title":"Clinical usefulness of PRECISE-DAPT score for predicting bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.","volume":"13","author":"Choi","year":"2020","journal-title":"Circ: Cardiovascular Interventions [Internet]"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12928-020-00651-9","article-title":"Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial.","volume":"36","author":"Watanabe","year":"2021","journal-title":"Cardiovasc Interv and Ther"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","article-title":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.","volume":"42","author":"Escaned","year":"2021","journal-title":"Eur Heart J"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jcin.2021.07.016","article-title":"3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation.","volume":"14","author":"Mehran","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ahj.2020.06.004","article-title":"Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial.","volume":"228","author":"Li","year":"2020","journal-title":"Am Heart J"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"e002427","DOI":"10.1161\/CIRCINTERVENTIONS.115.002427","article-title":"Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents.","volume":"8","author":"Koppara","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of st-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery.","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial.","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/apt.15059","article-title":"Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y12 inhibitors compared with clopidogrel.","volume":"49","author":"Guo","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2021.03.053","article-title":"P2Y12 inhibitor monotherapy versus conventional dual antiplatelet therapy or aspirin monotherapy in acute coronary syndrome: a pooled analysis of the SMART-DATE and SMART-CHOICE trials.","volume":"150","author":"Song","year":"2021","journal-title":"Am J Cardiol"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI.","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"e002816","DOI":"10.1161\/CIRCINTERVENTIONS.115.002816","article-title":"Clopidogrel versus aspirin as an antiplatelet monotherapy after 12-month dual-antiplatelet therapy in the era of drug-eluting stents.","volume":"9","author":"Park","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk.","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"e009565","DOI":"10.1161\/CIRCINTERVENTIONS.120.009565","article-title":"One-Month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients.","volume":"13","author":"Kandzari","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: A pre-specified analysis from the ZEUS trial.","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1093\/eurheartj\/ehx437","article-title":"Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102\u2009735 patients.","volume":"38","author":"D\u2019Ascenzo","year":"2017","journal-title":"Eur Heart J"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.carrev.2021.01.022","article-title":"Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE).","volume":"34","author":"Colleran","year":"2022","journal-title":"Cardiovasc Revasc Med"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:05:03Z","timestamp":1753812303000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001180","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}